Dificid (fidaxomicin) / Merck (MSD), Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   2 Trials   2 Trials   1263 News 


«12345678910111213...1617»
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  OpTION: Optimal Treatment for Recurrent Clostridium Difficile (clinicaltrials.gov) -  Dec 12, 2022   
    P4,  N=549, Recruiting, 
    We suggest that early identification of microbial community structures after FMT is of clinical value to predict response to the treatment. Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
    Journal:  Spore-Forming Clostridium (Clostridioides) difficile in Wastewater Treatment Plants in Western Australia. (Pubmed Central) -  Dec 9, 2022   
    The objective of this study was to characterize C. difficile in wastewater treatment plants (WWTPs) in Australia. We found that C. difficile can survive the treatment processes of WWTPs, and toxigenic C. difficile was being released into the environment, becoming a potential source/reservoir for CA-CDI.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Enrollment change, Trial completion date, Trial primary completion date:  Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin (clinicaltrials.gov) -  Nov 16, 2022   
    P3,  N=66, Recruiting, 
    The role of faecal microbiota transplantation (FMT) in second CDI recurrence is now clearer, but timing and mode of FMT in severe-complicated refractory disease still requires further study. N=98 --> 66 | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Zinplava (bezlotoxumab) / Merck (MSD)
    Review, Journal:  Severe Clostridioides difficile Infection in the Intensive Care Unit-Medical and Surgical Management. (Pubmed Central) -  Nov 12, 2022   
    Bezlotoxumab is suggested in recurrent cases within 6 months. If patients fail to improve within 3 to 5 days of therapy, especially in patients who have had nasogastric tubes or emergent surgery, fulminant colitis is possible and surgical consultation should be considered for total colectomy.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Reimbursement, Retrospective data, Journal:  Clostridioides difficile Treatment Protocol and Healthcare Burden. (Pubmed Central) -  Nov 3, 2022   
    If patients fail to improve within 3 to 5 days of therapy, especially in patients who have had nasogastric tubes or emergent surgery, fulminant colitis is possible and surgical consultation should be considered for total colectomy. No abstract available
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
    Review, Journal:  How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed? (Pubmed Central) -  Nov 2, 2022   
    The addition of bezlotoxumab might be considered if multiple additional risk factors for recurrent CDI exist, though the amount of evidence is low. Investigational approaches to reduce the effect of concomitant antibiotics on the gut microbiome could further optimise CDI treatment in the presence of concomitant antibiotic use in the future.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    PERIHEPATIC ABSCESS CAUSED BY CLOSTRIDIOIDES DIFFICILE: A RARE COMPLICATION () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_571;    
    Approximately 45% of extraintestinal CDI is found to be associated with direct inoculation of the pathogen caused by surgical interventions. Such patients were also immunocompromised and/or have multiple comorbidities.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Journal:  Clostridioides difficile infection: various therapeutic approaches (Pubmed Central) -  Oct 20, 2022   
    These choices have not been endorsed by the Swiss Infectious Diseases Society, which still proposes metronidazole as first-line treatment. As a matter of fact, this inexpensive treatment still presents a satisfactory efficacy on the strains of Clostridoides difficile found in Switzerland in the context of patients without risk factors and with low probability of relapse.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
    Clinical guideline, Review, Journal:  Is Three Company or a Crowd? Comparing and Contrasting U.S. and European Clostridioidesdifficile Clinical Practice Guidelines. (Pubmed Central) -  Sep 25, 2022   
    The emphasis on cost effective data was also a noticeable difference between the CPGs and thus interpretation of the available evidence. When using guidelines to help support local practice or institutional treatment pathways, clinicians should carefully balance CPG recommendations with local patient populations and feasibility of implementation, especially when multiple guidelines for the same disease state exist.
  • ||||||||||  ridinilazole (SMT 19969) / Summit Therap, Eurofarma
    Review, Journal:  Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. (Pubmed Central) -  Sep 20, 2022   
    Phase I and II clinical trials have been completed, with ridinilazole showing high tolerability and efficacy in treatment of CDI, and superiority over vancomycin in reducing recurrence of CDI within 30 days of treatment completion. Phase III trials are currently underway, the results of which may prove its potential to reduce recurrent CDI and lessen the heavy health and financial burden C. difficile imposes on patients and healthcare systems.